Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 4:14:1073939.
doi: 10.3389/fphar.2023.1073939. eCollection 2023.

Therapy by physician-pharmacist combination and economic returns for cancer pain management in China: a cost-effectiveness analysis

Xikui Lu  1   2   3 , Lu Zhang  1   2 , Hangxing Huang  1   2   3 , Xiangping Wu  1   2   3 , Zhenting Wang  1   2   3 , Ling Huang  1   2 , Jingyang Li  1   2 , Huimin Yu  1   2 , Hongyan Zhang  1   4 , Jian Xiao  1   2
Affiliations

Therapy by physician-pharmacist combination and economic returns for cancer pain management in China: a cost-effectiveness analysis

Xikui Lu et al. Front Pharmacol. .

Erratum in

Abstract

Objective: To examine whether joint management of cancer pain by physicians and pharmacists in clinics provides economic advantages from the perspective of the Chinese healthcare system. Methods: From February 2018 to March 2020, 100 patients who visited the joint cancer pain clinic at the Xiangya Hospital of Central South University were included. These patients were randomly assigned to either the control or intervention groups. The control group received regular outpatient services from a physician, while the intervention group received regular outpatient services from a physician and medication education provided by a pharmacist. The study considered various direct costs, including drug expenses, physician-pharmacist outpatient services, adverse event management, consultations, examinations, and readmissions. The outcome indicators considered were the cancer pain control rate and the reduction in pain scores. Decision tree modeling, single-factor sensitivity analysis, and probabilistic sensitivity analysis were performed to evaluate the cost-effectiveness of joint physician-pharmacist outpatient services compared to physician-alone outpatient services. Results: The intervention group showed a significantly higher cancer pain control rate than the control group (0.69 vs. 0.39, p = 0.03). In the decision tree model, the intervention group had a significantly lower pain score than the control group (0.23 vs. 0.14). The cost per person in the intervention group was $165.39, while it was $191.1 per person in the control group. The univariate sensitivity analysis showed that the cost of self-management for patients in the control group was identified as the primary sensitivity factor. Probabilistic sensitivity analysis indicated that the joint clinic group had a favorable incremental cost-effectiveness compared to the physician clinic group. In addition, the probabilistic sensitivity analysis demonstrated an absolute advantage in the incremental cost-effectiveness of the joint clinic group over the outpatient physician group. Conclusion: The participation of pharmacists in joint cancer pain clinic services led to improved pain management for patients, demonstrating a clear advantage in terms of cost-effectiveness.

Keywords: cancer pain; cost-effectiveness analysis; decision trees; economics; physician-pharmacist.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Decision-tree model for moderate to severe cancer pain.
FIGURE 2
FIGURE 2
Tornado diagram for one-way sensitivity analysis. pmADRcost1: The cost of adverse reactions in the intervention group. pmNADRcost2: The cost of no adverse effects in the intervention group. pmzrycost3: The readmission costs in the intervention group. pmycost4: The cost of pharmacist services in the intervention group. pADRcost5: The cost of adverse reactions in the control group. pNADRcost6: The cost of no adverse effects in the control group. pzrycost7: The cost of readmission in the control group. pzwcost8: The cost of pharmacist services in the control group. PMADRcc1: The treatment efficiency of adverse reactions in the intervention group. PMNADRcc2: The treatment efficiency of no adverse reactions in the intervention group. PMzrycc3: The readmission treatment efficiency in the intervention group. PMYScc4: The pharmacist-adjusted regimen service treatment efficiency in the intervention group. PADRcc5: The treatment efficiency of adverse reactions in the control group. PNADRcc6: The treatment efficiency of no adverse reactions in the control group. Pzrycc7: The readmission treatment efficiency in the control group. Pzwcc8: The pharmacist-adjusted regimen service treatment efficiency in the control group. PMzryr: The readmission rate in the intervention group. Pzryr: The rate of readmission in the control group. PMADRr: The incidences of adverse reactions in the intervention group. PADRr: The incidences of adverse reactions in the control group.
FIGURE 3
FIGURE 3
Plane scatter plot of incremental cost-effectiveness.
FIGURE 4
FIGURE 4
Cost-effectiveness acceptability curve.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Adam R., Bond C., Murchie P. (2015). Educational interventions for cancer pain. A systematic review of systematic reviews with nested narrative review of randomized controlled trials. Patient Educ. Couns. 98 (3), 269–282. 10.1016/j.pec.2014.11.003 - DOI - PubMed
    1. Can G., Mushani T., Rajhi B. H. A., Brant J. M. (2019). The global burden of cancer pain. Seminars Oncol. Nurs. 35 (3), 315–321. 10.1016/j.soncn.2019.04.014 - DOI - PubMed
    1. Copenhaver D. J., Huang M., Singh J., Fishman S. M. (2021). History and epidemiology of cancer pain. Berlin, Germany: Springer International Publishing, 3–15. - PubMed
    1. Feng W., Wang Y., Ran F., Mao Y., Zhang H., Wang Q., et al. (2022). The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study. Front. Med. (Lausanne) 9, 918468. 10.3389/fmed.2022.918468 - DOI - PMC - PubMed
    1. Liu K. (2019). Application of intelligent pharmaceutical service platform for the treatment of cancer pain in outpatient. Berlin, Germany: Springer.

LinkOut - more resources